De Reijke TM - Search Results

1

Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study.

Albrecht W, Collette L, Fava C, Kariakine OB, Whelan P, Studer UE, De Reijke TM, Kil PJ, Rea LA. Albrecht W, et al. Among authors: de reijke tm. Eur Urol. 2003 Nov;44(5):505-11. doi: 10.1016/s0302-2838(03)00375-0. Eur Urol. 2003. PMID: 14572746

2

Analysis of biopsy findings and implant quality following ultrasonically-guided 125I implantation for localised prostatic carcinoma.

Vijverberg PL, Blank LE, Dabhoiwala NF, de Reijke TM, Koedooder C, Hart AA, Kurth KH, González González D. Vijverberg PL, et al. Among authors: de reijke tm. Br J Urol. 1993 Oct;72(4):470-7. doi: 10.1111/j.1464-410x.1993.tb16180.x. Br J Urol. 1993. PMID: 7505191

3

Does prostate-specific antigen density alter decision making on biopsy?

Vleeming R, de Craen AJ, de Reijke TM, van Andel G, Kurth KH. Vleeming R, et al. Among authors: de craen aj, de reijke tm. Eur Urol. 1996;29(1):10-14. doi: 10.1159/000473710. Eur Urol. 1996. PMID: 8821683

4

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.

Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Dijkman GA, et al. Among authors: de reijke tm. J Urol. 1997 Jul;158(1):160-3. doi: 10.1097/00005392-199707000-00051. J Urol. 1997. PMID: 9186345 Clinical Trial.

5

Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial.

de Reijke TM, Keuppens FI, Whelan P, Kliment J, Robinson MR, Rea LA, Sylvester RJ. de Reijke TM, et al. J Urol. 1999 Nov;162(5):1658-64; discussion 1664-5. doi: 10.1097/00005392-199911000-00023. J Urol. 1999. PMID: 10524892 Clinical Trial.

6

Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.

Schröder FH, Collette L, de Reijke TM, Whelan P. Schröder FH, et al. Among authors: de reijke tm. Br J Cancer. 2000 Jan;82(2):283-90. doi: 10.1054/bjoc.1999.0916. Br J Cancer. 2000. PMID: 10646878 Free PMC article. Clinical Trial.

7

Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893.

Fosså SD, Curran D, Aaronson NK, Keuppens F, Kliment J, Robinson MR, DeReijke TM, Hetherington J, Kil PJ, Rea LA. Fosså SD, et al. Eur Urol. 2000 May;37(5):541-51. doi: 10.1159/000020191. Eur Urol. 2000. PMID: 10765092 Clinical Trial.

8

Transrectal ultrasound in the diagnosis of prostate cancer: state of the art and perspectives.

Sedelaar JP, Vijverberg PL, De Reijke TM, de la Rosette JJ, Kil PJ, Braeckman JG, Hendrikx AJ. Sedelaar JP, et al. Among authors: de reijke tm, de la rosette jj. Eur Urol. 2001 Sep;40(3):275-84. doi: 10.1159/000049787. Eur Urol. 2001. PMID: 11684843 Review.

9

Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update.

de Reijke T, Derobert E; Anandron /Nilutamide Study Group. de Reijke T, et al. Eur Urol. 2002 Aug;42(2):139-46. doi: 10.1016/s0302-2838(02)00272-5. Eur Urol. 2002. PMID: 12160584 Clinical Trial.

10

EORTC prostate cancer trials: what have we learnt?

de Reijke TM, Collette L. de Reijke TM, et al. Crit Rev Oncol Hematol. 2002 Aug;43(2):159-65. doi: 10.1016/s1040-8428(02)00028-8. Crit Rev Oncol Hematol. 2002. PMID: 12191738 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

264 results

Search Page

Filters